Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Familial adenomatous polyposis (FAP) is characterized by the development of hundreds to thousands of adenomas in the rectum and colon during the second decade of life.
Biomarker and diagnostic research for classic familial adenomatous polyposis has been reported in the published literature.
No approved treatments are currently available for classic familial adenomatous polyposis. An additional 11 compounds hold orphan drug designation.
While no drugs are FDA-approved specifically for classic familial adenomatous polyposis, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for classic familial adenomatous polyposis. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor |
|---|
Estimated prevalence: 1-9 in 100,000 (Uncommon).
27 clinical trials registered, 15 recruiting. Interventions under study include other interventions, drug therapy, procedural interventions, and medical devices. Pipeline includes 3 PHASE3, 3 PHASE2, 4 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07066046](https://clinicaltrials.gov/study/NCT07066046) |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 9:42 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about classic familial adenomatous polyposis
Designated
Exclusivity End |
|---|
Designation Status |
|---|
selective dual antagonist of the human prostaglandin E2 (PGE2) receptors EP2 and EP4 | selective dual antagonist of the human prostaglandin E2 (PGE2) receptors EP2 and EP4 | Tempest Therapeutics | 2025 | — | Designated |
beta-catenin antagonist | beta-catenin antagonist | Sapience Therapeutics, Inc | 2024 | — | Designated |
Microencapsulated Interleukin-10 | Microencapsulated Interleukin-10 | Therapyx, Inc. | 2023 | — | Designated |
3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-[(2-fluoro-4-iodophenyl)amino]-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione | 3-[(2R)-2,3-dihydroxypropyl]-6-fluoro-5-[(2-fluoro-4-iodophenyl)amino]-8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione | Recursion Pharmaceuticals, Inc. | 2021 | — | Designated |
encapsulated rapamycin | encapsulated rapamycin | Emtora Biosciences Inc | 2019 | — | Designated |
magnesium lysinate bis eicosapentaenoate | magnesium lysinate bis eicosapentaenoate | Thetis Pharmaceuticals | 2015 | — | Designated |
pyrvinium | pyrvinium | StemSynergy Therapeutics, Inc. | 2015 | — | Designated |
eflornithine plus sulindac | eflornithine plus sulindac | Panbela Therapeutics, Inc. | 2013 | — | Designated |
eicosapentaenoic acid | eicosapentaenoic acid | S.L.A. Pharma Ltd. (UK) | 2011 | — | Designated |
live attenuated E. Coli expressing Beta catenin shRNA | live attenuated E. Coli expressing Beta catenin shRNA | Marina Biotech | 2010 | — | Designated |
Valproic acid, sodium | Valproic acid, sodium | Topotarget A/S | 2005 | — | Withdrawn |
Gene therapy approaches for classic familial adenomatous polyposis have been reported in the published literature.
27 trials found
Artificial Intelligence-assisted Colonoscopy in the Detection and Characterization of Colorectal Lesions |
NA |
Instituto do Cancer do Estado de São Paulo |
RECRUITING |
[NCT06557733](https://clinicaltrials.gov/study/NCT06557733) | An Investigational Drug (TPST-1495) in Patients With Familial Adenomatous Polyposis | PHASE2 | National Cancer Institute (NCI) | RECRUITING |
[NCT06538402](https://clinicaltrials.gov/study/NCT06538402) | Ten Versus Fifteen Centimeter Pouch in IPAA Surgery | NA | Odense University Hospital | RECRUITING |
[NCT03050268](https://clinicaltrials.gov/study/NCT03050268) | Familial Investigations of Childhood Cancer Predisposition | — | St. Jude Children's Research Hospital | RECRUITING |
[NCT06614738](https://clinicaltrials.gov/study/NCT06614738) | Microbial and Environmental Factors Associated With Polyps Development in Familial Adenomatous Polyposis (MicrobEnvironment in FAP) | — | Hospices Civils de Lyon | RECRUITING |
157 publications have been identified in PubMed for classic familial adenomatous polyposis. Kisho has analyzed 97 by research type. Research spans Review / Meta-Analysis (46%), Epidemiology / Natural History (15%), and Basic Science / Preclinical (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 45 | 46% |
Disease patterns and progression | 15 | 15% |
Laboratory research | 14 | 14% |
Patient case studies | 9 | 9% |
Clinical study results | 7 | 7% |
Other research | 3 | 3% |
Testing and diagnosis research | 3 | 3% |
New treatment approaches | 1 | 1% |
Burgueño JF (2026). [PMID: 41344439](https://pubmed.ncbi.nlm.nih.gov/41344439/). *Cell Mol Gastroenterol Hepatol*. [Basic Science / Preclinical]
Van Egeren D (2026). [PMID: 41291291](https://pubmed.ncbi.nlm.nih.gov/41291291/). *Nature*. [Basic Science / Preclinical]
Tatsuta K (2026). [PMID: 41686831](https://pubmed.ncbi.nlm.nih.gov/41686831/). *PLoS One*. [Clinical Trial Publication]
Hüneburg R (2026). [PMID: 41972342](https://pubmed.ncbi.nlm.nih.gov/41972342/). *United European Gastroenterol J*. [Epidemiology / Natural History]
Bouchiba H (2026). [PMID: 41739006](https://pubmed.ncbi.nlm.nih.gov/41739006/). *Gastroenterology*. [Epidemiology / Natural History]
Maratt JK (2026). [PMID: 41504306](https://pubmed.ncbi.nlm.nih.gov/41504306/). *Am J Gastroenterol*. [Basic Science / Preclinical]
Karstensen JG (2026). [PMID: 41805273](https://pubmed.ncbi.nlm.nih.gov/41805273/). *Gastroenterology*. [Other]
Maria-Alexia P (2026). [PMID: 41771225](https://pubmed.ncbi.nlm.nih.gov/41771225/). *Cancer Genet*. [Review / Meta-Analysis]
Senda T (2026). [PMID: 42126588](https://pubmed.ncbi.nlm.nih.gov/42126588/). *Med Mol Morphol*. [Review / Meta-Analysis]
AbdullGaffar B (2026). [PMID: 41056600](https://pubmed.ncbi.nlm.nih.gov/41056600/). *Ann Diagn Pathol*. [Basic Science / Preclinical]